Formulation Brief & Sample Request Guide for Botanical & Adaptogen Actives

Key Technical Parameters #

Getting from “I want a botanical serum with adaptogen actives” to an approved formula takes more steps than most brand founders expect — and the gap between a vague brief and a useful one costs real time. This guide covers the mechanics of engaging an OEM formulation team for botanical and adaptogen actives: what to put in your brief, how we evaluate what you send us, what the sample-to-production path actually looks like, and where things typically stall. It’s written for brand owners who are ready to develop but haven’t been through this process before. The technical depth on specific botanicals is covered in other articles in this category; the focus here is the engagement process itself.

What Actually Determines Whether Your Brief Works #

Most briefs we receive open with a list of hero ingredients. That’s not wrong, but it’s also not where we start reading. The first thing we look at is what the product is supposed to do for the consumer — not what’s in it.

A brief that says “ashwagandha, reishi, 3% niacinamide, glass skin finish” tells us ingredients. A brief that says “morning serum for 28–35 year old urban consumers, key claim is visible radiance within 4 weeks, competitive benchmark is [Product X], no synthetic fragrance, EU-market launch” tells us a formulation target. Those are very different starting points, and the second one gets to a useful first sample faster.

The claim is the anchor. Everything else — actives selection, delivery system, pH, preservative system — flows from what you want to prove on pack and in market. For botanical actives specifically, this matters more than most people think, because the efficacy window for extracts like bakuchiol, centella, or adaptogenic mushroom extracts is narrow and concentration-dependent. A brief that says “add some bakuchiol” without a claim target gives us no way to dose it correctly on the first pass.

The format decision also front-loads regulatory work you can’t avoid. A leave-on serum at 2% bakuchiol has a different safety profile obligation than a wash-off format at the same concentration. Under EU Cosmetics Regulation 1223/2009, leave-on products with certain botanical actives trigger additional CPSR documentation requirements that affect development timeline by 6–10 weeks. We flag this at brief intake, not after stability is done.

How We Evaluate a Brief: The Intake Criteria We Actually Use #

When a brief comes through our intake process, we run it against what we call our BF-02 brief adequacy checklist before assigning formulation hours. There are six criteria. Briefs that clear all six go straight to formulation. Those that clear three or fewer go back to the brand with a brief clarification request. This isn’t gatekeeping — incomplete briefs result in wasted sample iterations, and most founders don’t want to pay for three rounds when one good round was possible.

The six criteria: (1) defined market and regulatory jurisdiction, (2) a specific texture or product format, (3) claim language or claim type (even directional is fine), (4) inclusion/exclusion list for ingredients, (5) a benchmark product or texture reference, and (6) budget range or cost-per-unit target.

That last one makes some brands uncomfortable. But honestly, the cost target changes formulation decisions materially. A $4.00 ex-works ceiling and a $14.00 ex-works ceiling produce different extract grades, different delivery systems, and different packaging options. We can work at both price points. We just need to know which world we’re designing for before we start.

On benchmarks specifically: you don’t need to give us a competitor name if that feels sensitive. A texture description plus a photo plus “I want something between these two” is enough. What we’re trying to avoid is the situation where we send a lightweight essence and you wanted a rich cream. We’ve iterated two full rounds on samples before because the texture reference was missing from the original brief. Not ideal for either side.

Brief-to-Sample Timeline: What the Stages Actually Look Like #

This is the section where expectations most often diverge from reality, so we’ll be specific.

Sample-to-production timeline for botanical active formulations, assuming no major brief changes after L1.

A few things worth flagging here. The 14–21 day L1 window assumes actives are in stock. For specialty adaptogens — certain grades of astragalus extract, standardized ashwagandha with >5% withanolide content, or HPLC-verified reishi — procurement can add 2–3 weeks. We maintain working stock of the 40 most-requested botanical actives, but anything outside that list has a lead time that we’ll flag at brief intake.

Stability is the step that surprises brands most. Accelerated stability at 40°C/75%RH runs for 8 weeks minimum before we make a go/no-go call on the formula. Real-time 24-month stability is initiated concurrently, but you can’t wait for 24 months before launch — the accelerated data is what drives your provisional sign-off. Under FDA Cosmetics Guidelines, there is no mandated stability protocol for cosmetics in the US, but most responsible OEM agreements and EU market requirements effectively mean 8 weeks accelerated is the floor. For NMPA registration in China, the bar is higher — NMPA Cosmetic Regulation requires stability data as part of the dossier for certain product categories, and the specific testing conditions differ from ICH norms.

The brand evaluation stage is the one we have least control over. When a brand takes 21 days to consolidate feedback on an L1 sample, the project effectively pauses. We hold formula slots for 30 days before releasing them back to queue. If you’re running multiple SKUs in parallel, coordinating your internal feedback cycle before samples arrive saves a lot of calendar time.

How to Evaluate Lab Samples — Criteria That Actually Predict Finished Product Performance #

Receiving your first lab samples is exciting. The evaluation step is also where a lot of brands make decisions they later regret. Here is how we recommend structuring the evaluation, based on what actually correlates with finished-product performance.

Texture and application: Evaluate on clean skin, not the back of your hand over fragrance or other product. Try it at both 20°C and body temperature. Botanical-rich formulas with high plant extract loads sometimes feel heavier cold and lighter warm — that’s normal. What you’re assessing is spreadability, absorption speed, and any tackiness or residue. If the finish doesn’t match your brief, flag it specifically: “too much slip,” “not enough dry-down” — not “it doesn’t feel right.”

Scent: Most botanical extracts carry a natural scent signature. Centella has a slight grassy note. Certain reishi and mushroom extracts carry an earthy undertone that becomes detectable at concentrations above 1.5%. If you’re targeting a fragrance-free product, this is the evaluation checkpoint where we confirm whether the natural extract scent falls within acceptable limits or whether we need to mask or substitute. We’ve had briefs where the brand requested 3% standardized ashwagandha extract with zero fragrance. The extract itself has an odor threshold that makes that combination technically difficult without a masking agent, which some clean beauty brands don’t want to add. We’d rather surface that tension at L1 than at production sign-off.

Efficacy proxies: You can’t run a consumer study on an L1 sample in 48 hours, obviously. What you can do is look at surrogate markers. For antioxidant claims on botanical & adaptogen actives, we provide DPPH radical scavenging data from our QC lab on each sample — typically reported as % inhibition relative to a standard concentration. This isn’t a clinical result, but it tells you whether the active is functional in the formula matrix. A formula with 2% bakuchiol and 0.5% vitamin C that shows lower DPPH inhibition than expected usually means the actives are interacting or the pH is wrong. We catch this internally before samples ship, but it’s data worth asking for.

For claims backed by existing clinical literature on the active itself, one anchor study worth knowing: a 2019 randomized, split-face controlled study (n=44, 12 weeks) evaluating 2% bakuchiol vs 0.5% retinol in a comparable emulsion base found equivalent reductions in fine line depth (approximately 20% for both, assessed via Visiometer), with the bakuchiol arm reporting statistically fewer tolerability events. That evidence supports a “retinol alternative” claim positioning, provided your formula uses bakuchiol in the 1.5–2% range in a compatible base at pH 5.0–5.5. Drop below pH 4.8 and bakuchiol oxidation accelerates noticeably in our experience — we’ve seen 15% active loss at 40°C/75%RH by week 6 when the pH wasn’t managed tightly. Above pH 6.2 and you lose emulsion stability in most oil-in-water systems we’ve tested with this active.

Stability red flags in early samples: Color shift and phase separation are the two most common early-stage indicators of formula problems. A sample that turns from pale amber to deep brown within 72 hours at room temperature almost always points to unprotected polyphenols interacting with trace metals. Our encapsulation technology approaches — primarily liposomal delivery for sensitive actives — mitigate this, but encapsulation adds cost that we’ll discuss in the next section.

Development Costs and MOQ: What You’re Actually Paying For #

Development fee structures in OEM work are less standardized than production pricing, and we’ve noticed brand owners often conflate the two. They’re different.

A development fee covers formulation scientist time, raw material procurement for lab batches, internal QC testing (microbial challenge, compatibility, preliminary stability), and documentation. At our lab, development fees for botanical actives formulations typically sit in the $800–$2,500 range per SKU depending on complexity. A single-phase serum with two or three botanicals at the lower end; a multi-phase adaptive emulsion with encapsulated actives at the higher end. That fee is non-refundable but is credited against production if you place an order above a defined MOQ threshold.

Per-unit production costs are separate and driven primarily by active concentration, delivery system, and fill size. The cost delta between a 1% and 3% standardized extract can be meaningful — not because the extract itself is expensive per gram, but because higher concentration often requires a different stabilization approach that affects the full formula BOM.

Sample MOQ for lab evaluation batches is typically 30–100g per variant, which is enough for your internal team, packaging compatibility testing, and any initial gifting or PR pre-launch. For pilot batches ahead of production, we typically run 5–10kg minimum, which allows us to confirm homogeneity, fill behavior, and in-process QC. First commercial production MOQ for most liquid and emulsion SKUs sits at 500 units minimum, though for specialized actives with longer procurement lead times, we may ask for 1,000 units to make the raw material sourcing economically sensible.

One thing worth being direct about: development fees are not a revenue line for us. We price them to cover real costs. A development fee that seems too low from another OEM usually means one of three things — low active concentrations regardless of what the brief says, recycled base formulas with minimal customization, or the cost is absorbed and recovered elsewhere in per-unit pricing. We’ve heard this enough from brands who switched to us after their first production run that we flag it here.

Moving from Sample Approval to First Production Batch #

This step involves more than pressing “go.” A few things need to be in place before production can start.

First, packaging specification has to be locked. We can’t finalize fill parameters, headspace, or viscosity adjustments without knowing the container dimensions, closure torque, and pump or cap format. Packaging compatibility testing — which checks for ingredient migration, seal integrity, and active degradation in the actual primary container — takes 4 weeks and runs concurrently with your late-stage stability review. Brands that arrive at production approval without confirmed packaging add 4–6 weeks to the timeline at the worst possible moment.

Second, regulatory documentation needs to be drafted for your target market before production, not after. For EU brands, the Cosmetic Product Safety Report requires a qualified assessor sign-off that references your final formula. For NMPA filing in China, the formula declaration and stability dossier are submitted before products reach consumers. Neither of these should be surprises, but they do require your market and channel to be confirmed before we can trigger the documentation process.

Third, the production order itself needs a confirmed purchase order with payment terms agreed. Standard at our facility for new brand partners is 30% deposit at order placement, 70% against bill of lading. Lead time from confirmed PO to ready-to-ship is typically 4–6 weeks for standard botanical formulations and up to 8 weeks for SKUs with specialized encapsulated actives or imported raw materials with longer procurement cycles.

The thing that most delays first production runs is actually none of the above. It’s indecision on minor formula changes after samples are approved. A request to “slightly adjust the scent” or “make it a tiny bit richer” after stability is complete means re-running stability on the modified formula. We always push back on late-stage minor changes, because the downstream cost in time is rarely worth the marginal improvement in texture. Once stability is done, the formula should be locked.

Formulation Notes for Brand Partners #

When you brief us on a botanical adaptogen project, the first things we need to know are: what market you’re launching in, what format the product takes, what the hero claim is, and whether there are any ingredient exclusions driven by your brand positioning. Those four questions change everything about how we approach the formulation.

The brief mistake we see most consistently is leading with an ingredient list built from trend research rather than a claim structure. A brand will come in with eight botanicals they want in the formula because they all appeared in trend reports that quarter. We almost always push back on this. More actives in the same formula don’t multiply efficacy — they increase interaction risk, complicate stability, and diffuse the claim narrative. A focused brief with two or three actives dosed at functional concentrations outperforms a crowded brief at sub-threshold concentrations on every metric that matters.

Timeline-wise: lab samples in 2–3 weeks from brief confirmation, accelerated stability over 8 weeks, 24-month real-time stability initiated at the same time as accelerated. Pilot batch runs in parallel with late-stage stability. If packaging is confirmed by the time stability completes, you can move to production sign-off without a gap. Total timeline from a clean, complete brief to a production-ready formula is typically 16–22 weeks.

Frequently Asked Questions #

How detailed does my brief need to be before you’ll start formulating?

A: You need to cover the six intake criteria we mentioned — market, format, claim direction, inclusion/exclusion list, texture reference, and cost range. You don’t need finished brand guidelines or final packaging specs at this stage. A two-page brief that answers those six questions is enough to start.

We want to launch in the EU and the US at the same time — does that change the sample process?

A: It changes the documentation path more than the formula itself. Under EU Cosmetics Regulation 1223/2009, you’ll need a CPSR before market entry; in the US under FDA Cosmetics Guidelines, the Modernization of Cosmetics Regulation Act (MoCRA) has added new registration and safety substantiation requirements. We flag both at brief intake and adjust the documentation schedule accordingly. The formula itself is usually the same — it’s the dossier work that diverges.

What happens to stability if we want to change something after the L2 sample is approved?

A: It depends on what changes. A colorant swap at the same pH doesn’t usually require a full stability re-run. A change to the active concentration or the emulsifier system does. We categorize change requests as minor, moderate, and major internally — major changes reset the stability clock. We’ve had projects where a last-minute fragrance addition at 0.6% caused emulsion instability in the primary packaging that didn’t show up until week 5 of accelerated testing. Lesson there was that the packaging hadn’t been locked when the fragrance was added. Both variables changed at once, which made root cause harder to isolate.

What’s the MOQ for a first production run?

A: Typically 500 units for standard botanical emulsions and serums. For formulas using encapsulated actives or specialty-grade adaptogens with longer raw material lead times, we may ask for 1,000 units minimum. Sample batches for evaluation are 30–100g per variant and are separate from the production MOQ.

Should we request multiple formula variants at L1 or just one?

A: We default to sending three variants unless the brief is highly constrained. The reasoning is practical — evaluating texture and finish across a range gives you a more calibrated reference point than evaluating one formula in isolation. Where we’ve seen brands go wrong with multiple variants is trying to cherry-pick features from each one and combine them into a new hybrid at L2. That’s rarely as straightforward as it sounds, and it often extends the revision cycle by an extra iteration. Pick the closest variant and give us specific delta feedback. That gets you to a final formula faster.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.